Biohaven Pharmaceutical Holding Co Ltd (BHVN) — Strategic Asset Allocation Index
Biohaven Pharmaceutical Holding Co Ltd (BHVN) has a Strategic Asset Allocation Index of 17.2% as of September 2023. Strategic assets (PP&E of $49.89 Million plus long-term investments of $-) total $49.89 Million, measured against net assets of $290.01 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Biohaven Pharmaceutical Holding Co Ltd Strategic Asset Allocation Index (2020–2022)
This chart shows how Biohaven Pharmaceutical Holding Co Ltd's Strategic Asset Allocation Index has evolved across 3 annual periods from 2020 to 2022. As of September 2023, the index stands at 17.2%, representing strategic assets of $49.89 Million against net assets of $290.01 Million USD. Explore Biohaven Pharmaceutical Holding Co Ltd (BHVN) cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Biohaven Pharmaceutical Holding Co Ltd (2020–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Biohaven Pharmaceutical Holding Co Ltd from 2020 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Biohaven Pharmaceutical Holding Co Ltd (BHVN) market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 9.7% | $52.14 Million | $52.14 Million | $0.00 | $538.77 Million | ▼ -12.2 pp |
| 2021 | 21.9% | $20.69 Million | $14.69 Million | $6.00 Million | $94.69 Million | ▼ -5.2 pp |
| 2020 | 27.0% | $20.74 Million | $13.56 Million | $7.18 Million | $76.78 Million | — |